Supplementary Table 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Autor: Deborah Ricci, George Mulligan, Dixie-Lee Esseltine, Andrew Cakana, Pier Luigi Zinzani, Ofer Shpilberg, Michael Crump, Sven de Vos, Joanna Romejko-Jarosinska, Adriana Teixeira, Simon Rule, Fritz Offner, Jiri Mayer, Adriana Scheliga, Xiaonan Hong, Evgenii A. Osmanov, Michael E. Schaffer, Helgi van de Velde, Yusri A. Elsayed, Panteli Theocharous, Alice Shapiro, Dana Gaffney, Reyna Favis, Jayaprakash D. Karkera, Erin D. Henitz, Weimin Li, Bertrand Coiffier
Rok vydání: 2023
DOI: 10.1158/1078-0432.22448841
Popis: Supplementary Table 1 PDF file 55K, Cut-points for protein markers used in different analyses. Cut-points selected for pair-wise comparisons were chosen to reduce the total number of comparisons that would be done. Cut-points for the discovery/confirmation analyses (see Supplementary Methods) were optimized based on enrichment of responders versus non-responders and reasonable population size
Databáze: OpenAIRE